File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis - A double-blind placebo controlled study

TitleEffects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis - A double-blind placebo controlled study
Authors
Issue Date1993
PublisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/
Citation
British Journal Of Rheumatology, 1993, v. 32 n. 11, p. 982-989 How to Cite?
AbstractMaxepa contains eicosapentaenoic acid (EPA) (171 mg/capsule) and docosahexaenoic acid (DHA) (114 mg/capsule). EPA acts as an alternative substrate to arachidonate, leading to the formation of the less proinflammatory prostaglandins ( '3' series) and leukotrienes ('5' series), If Maxepa has anti-inflammatory properties it could be expected to reduce the requirement for NSAIDs in patients with RA. This has not been investigated nor has Maxepa therapy been studied over a full 1-yr period. Sixty-four patients with stable RA requiring NSAID therapy only were studied. Patients received either 10 Maxepa or air-filled placebo capsules per day for 12 months. All then received placebo capsules for a further 3 months. Patients were reviewed at 3-monthly intervals. NSAID requirement at entry visit for each patient was assigned as 100%. Patients were instructed to slowly reduce their NSAID dosage providing there was no worsening of their symptoms. Clinical and laboratory parameters of RA activity were also measured. There was a significant reduction in NSAID usage in patients on Maxepa when compared with placebo from month 3 [mean (95% C.I. for mean) requirement 71.1 (55.9-86.2)% and 89.7 (73.7-105.7)%, respectively]. This effect reached its maximum at month 12 [40.6 (24.5-56.6)% and 84.1 (62.7-105.5)%, respectively and persisted to month 15 [44.7 (27.6-61.8)% and 85.8 (60.5-111.1)%, respectively] (P<0.00l, ANOVA). These patients were able to reduce their NSAID requirement without experiencing any deterioration in the clinical and laboratory parameters of RA activity.
Persistent Identifierhttp://hdl.handle.net/10722/162007
ISSN
2000 Impact Factor: 3.949
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, CSen_US
dc.contributor.authorMorley, KDen_US
dc.contributor.authorBelch, JJFen_US
dc.date.accessioned2012-09-05T05:16:35Z-
dc.date.available2012-09-05T05:16:35Z-
dc.date.issued1993en_US
dc.identifier.citationBritish Journal Of Rheumatology, 1993, v. 32 n. 11, p. 982-989en_US
dc.identifier.issn0263-7103en_US
dc.identifier.urihttp://hdl.handle.net/10722/162007-
dc.description.abstractMaxepa contains eicosapentaenoic acid (EPA) (171 mg/capsule) and docosahexaenoic acid (DHA) (114 mg/capsule). EPA acts as an alternative substrate to arachidonate, leading to the formation of the less proinflammatory prostaglandins ( '3' series) and leukotrienes ('5' series), If Maxepa has anti-inflammatory properties it could be expected to reduce the requirement for NSAIDs in patients with RA. This has not been investigated nor has Maxepa therapy been studied over a full 1-yr period. Sixty-four patients with stable RA requiring NSAID therapy only were studied. Patients received either 10 Maxepa or air-filled placebo capsules per day for 12 months. All then received placebo capsules for a further 3 months. Patients were reviewed at 3-monthly intervals. NSAID requirement at entry visit for each patient was assigned as 100%. Patients were instructed to slowly reduce their NSAID dosage providing there was no worsening of their symptoms. Clinical and laboratory parameters of RA activity were also measured. There was a significant reduction in NSAID usage in patients on Maxepa when compared with placebo from month 3 [mean (95% C.I. for mean) requirement 71.1 (55.9-86.2)% and 89.7 (73.7-105.7)%, respectively]. This effect reached its maximum at month 12 [40.6 (24.5-56.6)% and 84.1 (62.7-105.5)%, respectively and persisted to month 15 [44.7 (27.6-61.8)% and 85.8 (60.5-111.1)%, respectively] (P<0.00l, ANOVA). These patients were able to reduce their NSAID requirement without experiencing any deterioration in the clinical and laboratory parameters of RA activity.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/en_US
dc.relation.ispartofBritish Journal of Rheumatologyen_US
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal - Therapeutic Useen_US
dc.subject.meshArthritis, Rheumatoid - Drug Therapy - Physiopathologyen_US
dc.subject.meshDocosahexaenoic Acidsen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Combinationsen_US
dc.subject.meshEicosapentaenoic Aciden_US
dc.subject.meshErythrocyte Membrane - Metabolismen_US
dc.subject.meshFatty Acids - Blooden_US
dc.subject.meshFatty Acids, Omega-3 - Adverse Effects - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFish Oils - Adverse Effects - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPatient Satisfactionen_US
dc.titleEffects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis - A double-blind placebo controlled studyen_US
dc.typeArticleen_US
dc.identifier.emailLau, CS:cslau@hku.hken_US
dc.identifier.authorityLau, CS=rp01348en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid8220938en_US
dc.identifier.scopuseid_2-s2.0-0027515156en_US
dc.identifier.volume32en_US
dc.identifier.issue11en_US
dc.identifier.spage982en_US
dc.identifier.epage989en_US
dc.identifier.isiWOS:A1993ME68800008-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLau, CS=14035682100en_US
dc.identifier.scopusauthoridMorley, KD=7004388777en_US
dc.identifier.scopusauthoridBelch, JJF=7101752870en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats